insights_auto
Outlook: 82.1% bullish·0.0% bearish
Go to analysischevron_right
A1ZN34:BVMF
Astrazeneca Plc Bdr
133,40 R$
arrow_downward
-0,76%(-1,02) 1D
8 հոկ, 16:56:00 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1ZN34...
Open
134,50 R$
High
134,50 R$
Low
131,10 R$
Mkt. cap
246,42 մլրդ
Avg. vol.
732,00
Volume
613,00
52-wk high
190,40 R$
52-wk low
129,06 R$
Shares outstanding
1,55 մլրդ
No. of employees
96 հզր
Open
134,50 R$
High
134,50 R$
Low
131,10 R$
Mkt. cap
246,42 մլրդ
Avg. vol.
732,00
Volume
613,00
52-wk high
190,40 R$
52-wk low
129,06 R$
Shares outstanding
1,55 մլրդ
No. of employees
96 հզր
News stories
From web sources and news partners
Yahoo Finance
·
4 ժամ առաջ
AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth?
TipRanks
·
4 ժամ առաջ
AstraZeneca’s Liver Cancer Trial Completion: What It Means for AZN Investors
GeneOnline
·
12 ժամ առաջ
AstraZeneca Executes $2B Summit Investment to Advance Bispecific ADC Cancer Combos
Analytics Insight
·
13 ժամ առաջ
AstraZeneca vs GSK: Comparing Two UK Stocks in AI-Driven Healthcare
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About Astrazeneca Plc Bdr
CEOPascal Soriot
Employees96,1 հզր
Founded06 ապր, 1999 թ.
HeadquartersՔեմբրիջ, Cambridgeshire, Միացյալ Թագավորություն
Sector-
Websiteastrazeneca.com